HOOK has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
HOOK has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. HOOKIPA Pharma's total current liabilities for the quarter that ended in Mar. 2024 was $29.51
The historical data trend for HOOKIPA Pharma's Total Current Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HOOKIPA Pharma Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Total Current Liabilities | Get a 7-Day Free Trial | 14.76 | 21.14 | 27.65 | 35.63 | 41.99 |
HOOKIPA Pharma Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Total Current Liabilities | Get a 7-Day Free Trial | 44.21 | 46.25 | 40.58 | 41.99 | 29.51 |
Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.
HOOKIPA Pharma's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as
Total Current Liabilities | = | Accounts Payable & Accrued Expense | + | Short-Term Debt & Capital Lease Obligation |
= | 24.547 | + | 2.758 | |
+ | Other Current Liabilities | + | Current Deferred Liabilities | |
= | 0 | + | 14.683 | |
= | 41.99 |
HOOKIPA Pharma's Total Current Liabilities for the quarter that ended in Mar. 2024 is calculated as
Total Current Liabilities | = | Accounts Payable & Accrued Expense | + | Short-Term Debt & Capital Lease Obligation |
= | 22.131 | + | 2.728 | |
+ | Other Current Liabilities | + | Current Deferred Liabilities | |
= | -3.5527136788005E-15 | + | 4.649 | |
= | 29.51 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.
Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.
Be Aware
Stay away from companies that roll over the debt e.g. Bear Stearns
When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.
His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.
Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term
Thank you for viewing the detailed overview of HOOKIPA Pharma's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.
Reinhard Kandera | director, officer: Chief Financial Officer | C/O HOOKIPA PHARMA INC., 430 EAST 29TH ST., 14TH FLOOR, NEW YORK NY 10016 |
Jorn Aldag | director, officer: Chief Executive Officer | C/O UNUM THERAPEUTICS INC., 200 CAMBRIDGE PARK DRIVE SUITE 3100, CAMBRIDGE MA 02210 |
Mary Theresa Coelho | director | 52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017 |
Katia Schlienger | officer: Chief Medical Officer | 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK NY 10118 |
Malte Peters | director | TANGO THERAPEUTICS, INC., 100 BINNEY STREET, UNIT 700, CAMBRIDGE MA 02142 |
Timothy P. Reilly | director | C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK NY 10018 |
Gilead Sciences Inc | 10 percent owner | 333 LAKESIDE DR, FOSTER CITY CA 94404 |
Igor Matushansky | officer: Chief Medical Officer | C/O HOOKIPA PHARMA INC., 430 EAST 29TH STREET, NEW YORK NY 10016 |
Sofinnova Capital Vi Fcpr | 10 percent owner | C/O SOFINNOVA PARTNERS, 17 RUE DE SURENE, PARIS XX 75008 |
Christine D. Baker | officer: Chief Business Officer | C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK NY 10118 |
Jean-charles Soria | director | C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE SUITE 7240, NEW YORK NY 10118 |
Anders Lilja | officer: Sr. VP, Technical Development | C/O HOOKIPA PHARMA INC., 430 EAST 29TH ST., 14TH FLOOR, NEW YORK NY 10016 |
Klaus Orlinger | officer: Sr. VP, Research | C/O HOOKIPA PHARMA INC., 430 EAST 29TH STREET, 14TH FLOOR, NEW YORK NY 10016 |
Roman Necina | officer: Chief Technology Officer | C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK NY 10118 |
Forbion Capital Fund Ii Cooperatief U.a. | 10 percent owner | C/O HOOKIPA PHARMA INC., 430 EAST 29TH STREET, 14TH FLOOR, NEW YORK NY 10016 |
From GuruFocus
By sperokesalga sperokesalga • 06-01-2023
By Marketwired • 11-03-2023
By sperokesalga sperokesalga • 02-13-2023
By Marketwired • 10-18-2023
By Marketwired • 09-06-2023
By PRNewswire PRNewswire • 05-01-2023
By Marketwired • 08-10-2023
By Stock market mentor Stock market mentor • 01-04-2023
By sperokesalga sperokesalga • 06-10-2023
By Value_Insider Value_Insider • 12-15-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.